Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial

Crowley DC, Lau FC, Sharma P, et al. · International Journal of Medical Sciences

UC-II reduced total WOMAC by about 33% at 90 days versus about 14% with glucosamine+chondroitin, with parallel differences in VAS and Lequesne scores.

Population

Adults with knee osteoarthritis

Intervention

UC-II (undenatured type II collagen) 40 mg/day for 90 days

Comparator

Glucosamine 1500 mg + chondroitin 1200 mg daily (no placebo arm)

Limitations

Small (n=52), no placebo arm, funded by InterHealth Nutraceuticals (UC-II's maker); the comparator itself performs near placebo in independent trials.